Specialty Pharmaceuticals
ELYNVORA
A specialty pharmaceuticals portfolio built around high-need therapeutic areas — transplant immunology, neurology, oncology, and metabolic, cardio-renal and endocrine care.
Science you trust. For better health.
ELYNVORA is a specialty pharmaceuticals brand operating under the umbrella of ANADANI GROUP. It builds a high-quality portfolio of internationally sourced products with therapeutic value, delivered through strategic partnerships with trusted manufacturers. The portfolio spans eleven molecules across transplant immunology, neurology, oncology and metabolic, cardio-renal and endocrine care — all oral solid forms, supplied for professional use.
- 11 molecules
- 4 therapeutic areas
- Oral solid dose
- For professional use
About the brand
Reliable treatment options, sourced and supplied end to end.
Our mission
At ELYNVORA, we are committed to delivering high-quality pharmaceutical products through strategic partnerships with trusted manufacturers. Our mission is to provide reliable treatment options that address unmet medical needs and support better care for patients and partners across markets.
Our vision
To be a trusted specialty pharmaceuticals brand that bridges quality products, regulatory excellence, and operational reliability to deliver real value for our partners and the markets we serve.
Therapeutic areas
Four areas of high medical need.
ELYNVORA concentrates its portfolio where treatment options are specialised and reliability of supply matters most.
Transplant Immunology
Immunosuppressants used to prevent organ rejection after kidney, heart or liver transplantation, in combination with other therapies.
Neurology
Disease-modifying therapies for relapsing forms of multiple sclerosis, and antiepileptic treatment for partial-onset and generalized seizures.
Oncology
Targeted and cytotoxic therapies for prostate cancer, brain tumours, lung cancer and other solid tumours.
Metabolic, Cardio-Renal & Endocrine
Treatment for type 2 diabetes mellitus with demonstrated reduction of cardiovascular and renal risk.
The portfolio
Eleven molecules, four therapeutic areas.
Each product is listed with the indication, strength and dosage form printed on ELYNVORA’s own product documentation.
For professional use only. Refer to the package insert before prescribing. The information on this page reproduces ELYNVORA’s product documentation for healthcare professionals and trade partners. It is not medical advice, and it is not an offer to supply in any market where a product is not authorised.
Transplant Immunology
2 products
Mycophenolate Mofetil
500 mg
Film-coated tablets
Used to prevent organ rejection in patients receiving kidney, heart or liver transplants in combination with other immunosuppressants.
- Proven efficacy in prevention of organ rejection.
- Helps maintain long-term graft survival.
- Supports immunosuppression with a well-established safety profile.
Tacrolimus
0.5 mg / 1 mg / 5 mg
Capsules
Used to prevent organ rejection in patients receiving kidney, heart or liver transplants in combination with other immunosuppressants.
- Helps prevent organ rejection by suppressing the immune response.
- Maintains immune balance to protect the transplanted organ.
- Narrow therapeutic range — regular monitoring is recommended for safe use.
Neurology
3 products
Dimethyl Fumarate
240 mg
Delayed-release capsules
Used for the treatment of relapsing forms of multiple sclerosis (MS) to reduce relapse rate.
- Helps reduce relapse rate in relapsing forms of MS.
- Modulates the immune response to reduce inflammation.
- Proven efficacy in clinical studies.
Teriflunomide
14 mg
Film-coated tablets
Used for the treatment of relapsing forms of multiple sclerosis (MS) to reduce relapse rate.
- Proven efficacy in relapsing MS.
- Reduces relapse activity.
- Once daily, easy to take.
Levetiracetam
500 mg
Film-coated tablets
Used as adjunctive therapy in the treatment of partial-onset seizures in adults and children from 4 years of age, and primary generalized tonic-clonic seizures.
- Helps reduce seizure frequency.
- Broad spectrum efficacy.
- Well tolerated with a favorable safety profile.
Oncology
5 products
Enzalutamide
40 mg
Film-coated tablets
Used for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) to slow disease progression and extend survival.
- Improves overall survival in mCRPC patients.
- Targets androgen receptor signaling to inhibit cancer cell growth.
- Proven efficacy in clinical studies.
Abiraterone Acetate
250 mg
Film-coated tablets
Used in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
- Inhibits androgen production to slow cancer progression.
- Improves survival in patients with advanced prostate cancer.
- Proven efficacy in clinical studies.
Temozolomide
100 mg
Capsules
Used in the treatment of glioblastoma multiforme and other malignant gliomas, alone or in combination with radiation therapy.
- Alkylating agent that damages cancer cell DNA.
- Selective action on rapidly dividing cells.
- Proven efficacy in clinical studies.
Osimertinib
80 mg
Film-coated tablets
Used for the treatment of locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).
- Targets EGFR mutations including T790M.
- Proven efficacy in clinical studies with durable response.
- Once daily oral treatment.
Capecitabine
500 mg
Film-coated tablets
Used in the treatment of colorectal cancer and other solid tumors, alone or in combination with other anticancer therapies.
- Active oral chemotherapy (prodrug of 5-FU).
- Well established in multiple clinical guidelines worldwide.
- Convenient oral dosing for better compliance.
Metabolic, Cardio-Renal & Endocrine
1 product
Empagliflozin
10 mg / 25 mg
Film-coated tablets
Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular and renal events.
- Lowers blood glucose by promoting glucose excretion.
- Proven cardiovascular risk reduction in multiple clinical studies.
- Supports kidney health and slows progression of kidney disease.
- Well tolerated with a favorable safety profile.
Pack sizes, availability and regulatory status vary by market and are confirmed per order. Product images show ELYNVORA’s own carton artwork.
How we work
One integrated model, from portfolio to market.
A fully integrated approach covering all key stages of product development and supply.
Portfolio development
Selecting molecules with real therapeutic value for the markets ELYNVORA serves.
Partner selection & sourcing
Building strategic partnerships with trusted manufacturers, and qualifying them before supply begins.
Regulatory compliance & quality assurance
Meeting the documentation and quality requirements of each destination market.
Supply chain management
Planning and controlling supply so committed volumes arrive when they are needed.
Distribution & market partnerships
Reaching healthcare systems through long-term distribution and market partners.
Quality commitment
Committed to quality. Dedicated to health.
Manufactured to high quality standards
Every product in the portfolio is manufactured to high quality standards, as stated on each of ELYNVORA’s product sheets.
Trusted by healthcare professionals worldwide
The molecules in this portfolio are established treatments, used by healthcare professionals internationally.
Marketing authorisation, manufacturing site and certification status are confirmed per product and per market on request. None is stated on this page, because none is stated in ELYNVORA’s own product documentation.
Our values
Five commitments, applied daily.
Quality
We are committed to the highest standards of quality, safety, and efficacy in everything we do.
Integrity
We build trust through transparency, honesty, and responsible business practices.
Innovation
We seek smarter solutions to address evolving healthcare needs and deliver better outcomes.
Partnership
We build long-term relationships based on trust, respect, and shared success.
Responsibility
We are committed to contributing to healthier societies and a more sustainable future.
Also from the group
The same standard, on the factory floor.
LUXSAFE is the group’s safety footwear brand, certified to EN ISO 20345. It is the other half of one idea: whether it is a medicine or a boot, what makes it trustworthy is a written specification, a qualified manufacturer and the paperwork to prove it.
Let's build a lasting partnership.
Tell us what you need — a product specification, a quotation, a distribution agreement, or representation in a new market.
Luxembourg